全文获取类型
收费全文 | 44154篇 |
免费 | 3533篇 |
国内免费 | 114篇 |
专业分类
耳鼻咽喉 | 332篇 |
儿科学 | 1454篇 |
妇产科学 | 1216篇 |
基础医学 | 5594篇 |
口腔科学 | 836篇 |
临床医学 | 7350篇 |
内科学 | 7527篇 |
皮肤病学 | 607篇 |
神经病学 | 4287篇 |
特种医学 | 952篇 |
外科学 | 3922篇 |
综合类 | 685篇 |
一般理论 | 81篇 |
预防医学 | 6065篇 |
眼科学 | 513篇 |
药学 | 2678篇 |
中国医学 | 30篇 |
肿瘤学 | 3672篇 |
出版年
2023年 | 272篇 |
2022年 | 304篇 |
2021年 | 734篇 |
2020年 | 604篇 |
2019年 | 1030篇 |
2018年 | 1067篇 |
2017年 | 842篇 |
2016年 | 964篇 |
2015年 | 1063篇 |
2014年 | 1408篇 |
2013年 | 2113篇 |
2012年 | 3022篇 |
2011年 | 3050篇 |
2010年 | 1650篇 |
2009年 | 1493篇 |
2008年 | 2787篇 |
2007年 | 2946篇 |
2006年 | 2900篇 |
2005年 | 2816篇 |
2004年 | 2649篇 |
2003年 | 2578篇 |
2002年 | 2396篇 |
2001年 | 561篇 |
2000年 | 517篇 |
1999年 | 553篇 |
1998年 | 595篇 |
1997年 | 428篇 |
1996年 | 397篇 |
1995年 | 390篇 |
1994年 | 364篇 |
1993年 | 341篇 |
1992年 | 388篇 |
1991年 | 330篇 |
1990年 | 291篇 |
1989年 | 287篇 |
1988年 | 260篇 |
1987年 | 254篇 |
1986年 | 257篇 |
1985年 | 280篇 |
1984年 | 219篇 |
1983年 | 228篇 |
1982年 | 209篇 |
1981年 | 217篇 |
1980年 | 202篇 |
1979年 | 132篇 |
1978年 | 139篇 |
1977年 | 112篇 |
1976年 | 119篇 |
1975年 | 104篇 |
1974年 | 115篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
3.
4.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
5.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
Factors predicting the development of pressure ulcers in an at‐risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
8.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献9.
10.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献